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Background: Behavioral changes are common in patients with multiple sclerosis (MS), 
however not as readily recognized as cognitive impairments.
Objective: The aim of this study was to analyze behavioral changes and its relation to 
disease characteristics, disability, and cognitive impairments in patients with MS.
Method: This is a single-center cross-sectional study. A detailed neuropsychological 
examination, including the Frontal Systems Behavior Scale (FrSBe), the Beck depression 
inventory (BDI), and the Wuerzburg Fatigue Inventory for Multiple Sclerosis (WEIMuS) 
test, was performed. FrSBe results were correlated with disease characteristics, disabil-
ity, and cognitive assessments.
results: 66 patients were enrolled (mean age: 43.4 years; disease duration: 9.3 years; 
Expanded Disability Status Scale: 3.0). Up to one third of patients showed behavioral 
changes in at least one domain or the total score of the FrSBe. Patients were mildly 
affected with regard to cognitive functioning. Consistent correlation was found between 
behavioral changes and fatigue (WEIMuS) and depressive symptoms (BDI), but not 
with disease characteristics, disability, or cognitive functions. There was an increase of 
behavioral changes on all FrSBe scales in the current status compared to the retrospec-
tively rated status before disease onset. Self- and family ratings with regard to current 
behavioral changes were similar.
conclusion: Behavioral changes are common in otherwise mildly affected MS patients 
with up to one third being affected. In this patient cohort, behavioral changes occur 
largely independent of disease characteristics, physical disability, and cognitive function-
ing but correlate with both fatigue and depressive symptoms. Therefore, they should be 
tested specifically.
Keywords: multiple sclerosis, cognition, behavioral changes, Frontal systems Behavior scale, disability evaluation
inTrODUcTiOn
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system character-
ized by inflammation, demyelination, axonal injury, and axonal loss. MS affects gray and white 
matter of the whole brain and spinal cord eventually leading to diffuse gray and white matter 
atrophy (1).
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Behavioral changes are common and manifold in MS with 
depressive symptoms being the most frequent reported neu-
ropsychiatric manifestation with a lifetime prevalence rate of 
about 50% (2–4).
Other common neuropsychiatric manifestations include labil-
ity (41%), irritability (38%), inflexibility (26%), aggression (23%), 
impatience (22%), apathy (22%), adjustment disorder (17%), and 
obsessive-compulsive disorder (15%) (5). Behavioral changes 
are relevant because they negatively influence activities of daily 
living and contribute to poor quality of life and unemployment 
together with other symptoms such as physical disability and 
cognitive deficits (6–8). In addition, behavioral changes can be 
predictive of cognitive and functional impairment in MS patients 
(6, 9). Despite their frequency and relevance, behavioral changes 
receive little attention in the daily care of MS patients and in clini-
cal trials. This is at least partly due to difficulties in assessing and 
quantifying behavioral changes.
In contrast, cognitive impairments can be evaluated and 
quantified more easily. In MS patients, cognitive impairments 
such as deficits in complex attention, efficiency of information 
processing, executive functioning, processing speed, and long-
term memory are typical and noted early in the disease course 
(6, 9–12). The goal of the present study was to analyze behavioral 
changes in patients with MS with regard to its frequency and 
the patient population in whom behavioral changes can be 
predominantly expected. These are important information in 
the management of MS patients. To do so, the Frontal Systems 
Behavior Scale (FrSBe) that analyzes behavioral changes related 
to frontal lobe disturbances (apathy, disinhibition, and executive 
dysfunction) was correlated to MS-specific disease character-
istics, disability, cognitive impairment, as well as depressive 
symptoms and fatigue (3, 6, 9, 12, 13).
Furthermore, we wanted to analyze the difference in asking 
patients and significant others in evaluating behavioral changes 
to gain information on the optimal way to evaluate behavioral 
changes in patients with MS in the daily practice and in clinical 
trials.
We hypothesized that behavioral changes (1) correlate with 
more severe disease stages with regard to general disability and 
disease duration, (2) correlate with cognitive impairments and 
especially with frontal lobe dysfunctions, (3) correlate with 
fatigue and depressive symptoms as shown in previous studies 
(3, 6, 9). Furthermore, we hypothesized that there is a difference 
in asking patients and significant others in rating behavioral 
changes as shown in previous studies in MS and in other brain 
diseases (13–17).
MaTerials anD MeThODs
Patients
Consecutive patients with clinically isolated syndrome (CIS), 
relapsing-remitting MS, secondary progressive MS, or primary 
progressive MS (PPMS), according to the 2010 McDonald’s 
criteria, were recruited from our outpatient clinic (18). Main 
exclusion criteria were relapses and/or steroid treatment within 
the preceding 2  months and additional diseases or conditions 
apart from MS that affect behavioral changes or compromise the 
adequate performance of the study procedures.
study Design
This was a single-center, cross-sectional study. Patient char-
acteristics were obtained from the last visit in the outpatient 
clinic including the Expanded Disability Status Scale (EDSS) 
that was performed by certified level C raters (http://neuro-
status.net) (19).
All additional tests were performed in one extra session by 
a neuropsychologist (SK-E). Each patient provided written 
informed consent prior to study entry, and the study was approved 
by the ethics committee of the canton of Bern, Switzerland.
cognitive evaluations
The used tests were primarily selected to assess the main neu-
ropsychological functions. Unless otherwise stated, tests were 
taken from “Materials and Norms for the Neuropsychological 
Diagnostics,” and normal values were available for all tests 
(20). Tests for verbal and visual short-term memory included 
the Digit Span Forward and a Block Tapping test. To measure 
learning and long-term memory, the Rey Auditory Verbal 
Learning test, the Rey Visual Design Learning test, and the 
delayed recall of Logical Memory of the Wechsler Memory 
Scale and the delayed recall (30′) of Rey’s Complex Figure 
were used. Performance on executive functions were assessed 
with a Word and Design fluency task, Stroop’s Color-Word 
test, a Planning (tower) test, and the Kramer’s test, i.e., a Card 
Sorting test. Tests for measuring different aspects of attention 
included two subtests (alertness and divided attention) of the 
computerized test battery of Zimmermann and Fimm (21), the 
Test des Deux Barrages (assessing focused attention), and an 
extended German version of part A of the Trail Making test. 
Visuospatial constructional ability was tested by means of copy-
ing the Complex Figure of Rey. A test called Spatial test assessed 
mental rotation.
Tests without normative data included the Bells test (assessing 
neglect; cut-off: 6 of maximum 36 omissions); the test of upper 
limb apraxia (TULIA; cut-off: 194 of maximum 240 points); lan-
guage tasks assessing comprehension (short version of the token 
test); naming, reading, and writing (each of these maximum 10 
points); and the Cortical Vision Screening test (maximum 38 
points) (22).
Behavioral evaluation
The FrSBe assesses behavioral changes related to frontal lobe 
disturbances, which includes apathy, disinhibition, and executive 
dysfunction that contribute to a total score (23). It is filled out by 
the patient (“self-report form”) and additionally by a designated 
significant other or family member (“family form”), retrospec-
tively with regard to the behavioral status before first symptoms of 
MS (called “before illness”) and with regard to the current status 
(called “after illness”). The FrSBe was shown to be a sensitive 
measure of behavioral changes and a predictor of neuropsycho-
logical deficits and poor adaptive function in patients with MS. 
It was validated using a healthy control group and normal values 
are available (6, 9).
TaBle 1 | Patients characteristics (n = 66).
Age (years), mean ± SD (range) 43.4 ± 11.9 (21–68)
Gender (female), % 75.8
Education duration (years), mean ± SD (range) 13.2 ± 2 (9–18)
Disease duration (years), mean ± SD (range) 9.3 ± 7.9 (0.5–46.2)
EDSS, mean ± SD (range) 3.0 ± 1.6 (0–7)
EDSS distribution, n (%)
0.0–0.5 1 (1.5%)
1.0–1.5 16 (24.2%)
2.0–2.5 19 (28.8%)
3.0–3.5 11 (16.7%)
4.0–4.5 10 (15.2%)
5.0–5.5 2 (3%)
6.0–6.5 6 (9.1%)
7.0 1 (1.5%)
MS type, n (%)
CIS 4 (6%)
RRMS 52 (79%)
SPMS 8 (12%)
PPMS 2 (3%)
Immunomodulatory therapy, n (%)
Interferon beta 23 (34.8%)
Natalizumab 20 (30.3%)
Glatirameracetate 6 (9.1%)
Mitoxantrone 3 (4.6%)
Azathioprine 1 (1.5%)
No therapy 13 (19.7%)
n, number; EDSS, Expanded Disability Status Scale; CIS, clinically isolated syndrome; 
RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple 
sclerosis; PPMS, primary progressive multiple sclerosis.
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The Beck Depression Inventory (BDI) test to evaluate depres-
sive symptoms (24), the Wuerzburg Fatigue Inventory for Multiple 
Sclerosis (WEIMuS) test to evaluate fatigue (25), and the FrSBe 
(23) were performed.
statistical analysis
Statistical analyses were exploratory and were performed using 
R (version 3.1.2, R Core Team) (26). Analyses were based on all 
evaluable patients, and missing values were not imputed. Normal 
values were available for all analyses. Unless otherwise stated, 
normalized T scores corrected for age, sex, and education were 
calculated. T scores have a mean of 50 and a SD of 10. With 
the exception of the FrSBe, T scores ≤35 are pathological, and 
T scores of 36–40 may be interpreted as borderline impairment. 
With respect to FrSBe, T scores ≥65 are pathological. T scores of 
60–64 may be interpreted as borderline impairment.
The relationship of behavioral changes measured by the FrSBe 
and disease characteristics (age, gender, education, disease dura-
tion, MS type, and treatment) as well as disability (EDSS) was 
assessed by multivariable analysis of covariance. To analyze the 
relationship of behavioral changes to the neuropsychological 
and behavioral evaluations, Spearman rank correlation coef-
ficients were calculated between the FrSBe self- and family-form 
postillness with all neuropsychological tests, the BDI, and the 
WEIMuS. The level of significance of two-sided statistical tests 
was set at p = 0.05, and no correction for multiple testing was 
applied.
To improve sensitivity to the different cognitive domains, 
additional mean scores of the respective tests for the domains 
“Verbal memory,” “Non-verbal memory,” “Executive function,” 
“Attention,” “Visuospatial Abilities/Visual perception,” and 
“Language” were calculated and correlated to the FrSBe as well 
(see above, Tables 2 and 4).
The differences in the assessment of behavioral changes by 
patients and by significant others, the “self-report form” of the 
FrSBe (filled out by the patient), and the “family form” of the 
FrSBe (filled out by a designated significant other or family 
member), with regard to the behavioral status before the first 
symptoms of MS (called “before illness”) and the current sta-
tus (called “after illness”), were compared using the Wilcoxon 
signed-rank test.
resUlTs
Patient Population
66 consecutive patients were included. The characteristics of the 
study population regarding age, gender, education and disease 
duration, mean EDSS, EDSS distribution, MS type, and current 
immunomodulatory therapy are shown in Table 1. There were no 
relevant comorbidities. Non-steroidal anti-inflammatory drugs 
and antidepressants were the most common additional medical 
treatments. Patients with higher EDSS scores had more muscle 
relaxants.
The descriptive results of the cognitive and behavioral tests 
including the prevalence of pathological test results are outlined 
in Table 2.
cognitive Test results
With regard to cognitive functions, patients were largely unim-
paired in memory, executive functions, visuospatial abilities/
perception, neglect, apraxia, and language (pathological values 
most often in less than 10% of patients), with the exception of 
planning abilities. In different aspects of attention, we found 
deficits in up to 23% of patients (Table 2).
Behavioral Test results
With regard to the FrSBe, the total score for behavioral self-
ratings showed pathological values in 11.47% before and 
24.59% after illness. With regard to the behavioral domains 
of the FrSBe, i.e., apathy, executive dysfunction, or disinhibi-
tion, up to 11.47% patients before and up to 27.9% patients 
after illness showed pathological values in at least one domain. 
There was a significant increase after illness compared to before 
illness in all FrSBe scales (all p < 0.0001) except for the domain 
“disinhibition” that showed a non-significant trend (p = 0.08) 
(Figure 1).
Behavioral family rating of the FrSBe showed a pathological 
total score in 12.12% before illness and 30% after illness and in 
up to 12.1% before illness and up to 33.3% after illness in one of 
the examined FrSBe domains (Table 2). There was a significant 
increase of all FrSBe scales after illness compared to before illness 
(all p < 0.0001) (Figure 1).
In the BDI, 36% of patients did not have depressive symptoms, 
59.1% showed minimal to medium depressive symptoms, and 
4.9% heavily depressive symptoms (Table 2).
TaBle 2 | Results of cognitive and behavioral tests (n = 66).
cognitive and behavioral 
tests
T value, unless indicated 
witha, mean ± sD (range)
Prevalence of 
pathological 
values, n (%)
Verbal memory
Verbal short-term memory 54.37 ± 7.73 (39–72) 0/66 (0%)
Auditory verbal learning and 
memory test (learning)
45.92 ± 8.31 (25–65) 6/66 (10%)
Auditory verbal learning and 
memory test (long-term recall)
50.21 ± 10.8 (22–64) 5/66 (7.58%)
Logical Memory of the 
Wechsler Memory test
52.34 ± 7.53 (37–72) 0/66 (0%)
Mean values of verbal memory 
tests
50.59 ± 5.83 (30.75–62.75)
non-verbal memory
Visual short-term memory 52.75 ± 9.24 (25–77) 3/66 (4.55%)
Figural learning and memory 
test (learning)
48.27 ± 9.07 (21–65) 4/65 (6.15%)
Figural learning and memory 
test (long-term recall)
48.68 ± 10.18 (20–64) 5/64 (7.81%)
Recall of Rey-Taylor complex 
figure test
53.83 ± 8.98 (20–79) 1/66 (1.52%)
Mean values of non-verbal 
Memory tests
50.89 ± 6.4 (34.25–66.25)
executive functions
Word fluency task 47.40 ± 8.68 (31–72) 5/66 (7.58%)
Design fluency task 50.12 ± 7.82 (28–64) 3/66 (4.55%)
Stroop’s color-word test III 
(mistakes)
49.98 ± 8.51 (32–58) 2/66 (3.03%)
Stroop’s color-word test III 
(time)
52.66 ± 14.96 (28–79) 7/66 (10.61%)
Planning test (number of 
moves)
46.73 ± 10.73 (28–65) 11/64 (17.19%)
Planning test (quality total) 49.21 ± 10.91 (31–65) 7/64 (10.94%)
Kramer’s card sorting test 54.51 ± 7.38 (38–62) 0/66 (0%)
Mean values of executive 
functions tests
50.12 ± 5.42 (38–63.71)
attention
Alertness without warning 
signal
43.6 ± 10.19 (27–84) 11/65 (16.92%)
Alertness with warning signal 41.55 ± 8.12 (24–63) 15/65 (23.08%)
Divided attention 45.07 ± 9.41 (27–62) 12/65 (18.46%)
Test des deux barrages (total 
per minute)
42.04 ± 7.50 (20–55) 9/63 (14.29%)
Test des deux barrages 
(omission)
49.30 ± 8.39 (32–67) 2/63 (3.17%)
Test des deux barrages 
(constancy)
47.15 ± 11.0 (28–76) 8/63 (12.7%)
Modified Trail Making Test 
Form A
47.66 ± 8.6 (20–60) 4/57 (7.02%)
Mean values of attention tests 44.98 ± 4.96 (31.67–54.57)
Visuospatial abilities/visual perception
Rey-Taylor complex figure test 
(copy)
51.84 ± 4.34 (35–53) 4/66 (6.06%)
Spatial test 52.74 ± 7.7 (30–60) 1/66 (1.52%)
Cortical Vision Screening test 
(maximum 38)
37.81a ± 0.81 (32–38) 0/66 (0%)
Mean values of visuospatial 
abilities/visual perception tests
47.6 ± 3.41 (32.33–52)
neglect
Bells test (omissions; cut-off 6) 0.96a ± 1.24 (0–5) 0/63 (0%)
apraxia
Apraxia total (TULIA) 216.93a ± 10.87 (193–237) 3/59 (5.08%)
cognitive and behavioral 
tests
T value, unless indicated 
witha, mean ± sD (range)
Prevalence of 
pathological 
values, n (%)
language
Token test (maximum 10) 10a ± 0 (10) 0/66 (0%)
Naming (maximum 10) 9.96a ± 0.25 (8–10) 0/66 (0%)
Reading (maximum 10) 10a ± 0 (10) 0/64 (0%)
Writing (maximum 10) 9.91a ± 0.52 (6–10) 0/66 (0%)
Mean values of language  
tests
9.97 ± 0.14 (9–10)
Frontal system Behavior scale
Before
Self-rating
Apathy 48.09 ± 10.26 (30–85) 3/61 (4.91%)
Disinhibition 53.04 ± 10.23 (35–79) 7/61 (11.47%)
Executive dysfunction 50.86 ± 10.61 (33–88) 5/61 (8.47%)
Total 51.24 ± 10.43 (37–95) 7/61 (11.47%)
Family rating 
Apathy 46.55 ± 10.52 (28–72) 4/59 (6.77%)
Disinhibition 48.45 ± 10.66 (28–71) 5/59 (8.19%)
Executive dysfunction 51.84 ± 13.28 (28–97) 8/59 (12.12%)
Total 49.27 ± 11.45 (25–77) 8/59 (12.12%)
After
Self-rating
Apathy 59.78 ± 15.64 (32–111) 17/61 (27.86%)
Disinhibition 54.42 ± 9.92 (40–79) 14/61 (22.95%)
Executive dysfunction 55.91 ± 12.48 (33–91) 14/61 (22.95%)
Total 58 ± 12.0 (36–90) 15/61 (24.59%)
Family rating 
Apathy 55.08 ± 15.09 (28–93) 11/60 (10.00%)
Disinhibition 54.46 ± 13.76 (28–91) 17/60 (27.86%)
Executive dysfunction 55.95 ± 15.18 (28–93) 20/60 (33.33%)
Total 56.85 ± 15.11 (25–100) 18/60 (30%)
BDi 12.34a ± 7.95 (0–36)
0–8 (none depressive 
symptoms)
22/61 (36.06%)
9–13 (minimal depressive 
symptoms)
16/61 (26.22%)
14–19 (mild depressive 
symptoms)
13/61 (21.31%)
20–28 (medium depressive 
symptoms)
7/61 (11.47%)
>29 (heavily depressive 
symptoms)
3/61 (4.91%)
WeiMus
Physically, comparison with HC 61.54 ± 14.81 (39–89) 8/62 (12.90%)
Cognitive, comparison  
with HC
60.41 ± 13.87 (40–88) 14/62 (22.58%)
Total, comparison with HC 61.11 ± 14.53 (39–91) 10/62 (16.12%)
Physically, comparison  
to PwMS
43.83 ± 11.43 (26–65) 8/62 (12.90%)
Cognitive, comparison  
to PwMS
47.62 ± 9.76 (33–68) 11/62 (17.74%)
Total, comparison to  
PwMS
45.51 ± 11.38 (28–68) 11/62 (17.74%)
The results of each cognitive or behavioral test are shown and mean values of 
tests contributing to the cognitive domains “Verbal memory,” “Non-verbal memory,” 
“Executive function,” “Attention,” “Visuospatial Abilities/Visual perception,” and 
“Language” were calculated; T scores ≤35 are pathological except for the FrSBe in 
which T value >65 are pathological.
aRaw value of scale.
n, number, HC, healthy controls; PwMS, patients with multiple sclerosis; BDI, Beck 
Depression Inventory; WEIMuS, Wuerzburg Fatigue Inventory for Multiple Sclerosis 
test; FrSBe, Frontal Systems Behavior Scale.(Continued)
TaBle 2 | Continued
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FigUre 1 | Behavioral changes before vs. after illness.
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FigUre 2 | Behavioral changes: self- vs. family rating.
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TaBle 3 | Contribution (coefficients) of disease characteristics to behavioral changes.
FrsBe self-ratings FrsBe family ratings
apathy Disinhibition executive 
dysfunction
Total score apathy Disinhibition executive 
dysfunction
Total score
Age 0.11 −0.065 0.18 0.17 0.05 −0.25 −0.06 −0.04
Female vs. male 6.97 7.84† 5.81 7.78* 5.77 3.65 5.11 4.8
Education duration (years) −0.14 0.82 0.32 0.48 −0.8 0.08 0.155 −0.16
Disease duration (years) −0.34 −0.03 −0.25 −0.205 0.6 0.77† 0.3 0.62*
Examination duration (minutes) 0.47 −4.96* −0.39 −2.0 1.04 1.84 −0.26 0.35
MS type
CIS vs. RRMS −7.79 −0.465 −5.095 −5.71 5.97 11.51 1.695 6.15
SPMS vs. RRMS 3.03 −0.94 −2.68 1.355 9.46 −0.465 −4.9 4.78
PPMS vs. RRMS −7.25 9.775 −7.32 −3.07 24.15† 30.88† 2.85 24.36*
EDSS 2.72 2.88† 2.79 2.7 0.23 1.11 2.71 1.11
Not treated vs. treated 3.97 0.62 2.08 2.26 −6.94 −13.42† −0.3 −6.72
*p < 0.05.
†p < 0.01.
EDSS, Expanded Disability Status Scale; CIS, clinically isolated syndrome; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; PPMS, 
primary progressive multiple sclerosis; FrSBe, Frontal Systems Behavior Scale.
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The WEIMuS showed higher rates of cognitive than physical 
fatigue, with rates of up to 22.58% compared to healthy controls 
and up to 17.74% compared to MS patients (Table 2).
The TULIA showed three patients with mild apraxia 
(4.5% of study population) and none with moderate or severe 
apraxia (normal values taken from the studs by Vanbellingen 
et al.) (27).
comparison of Patients and significant 
Others in rating Behavioral changes
Self-ratings and family ratings of the FrSBe did not show 
significant differences except for the domains “apathy after 
illness” and “disinhibition before illness” (p  =  0.0407 and 
p = 0.0066, respectively), with higher values in the self-ratings 
(Figure 2).
correlation of Behavioral changes  
(FrsBe results) with Ms Disease- 
specific characteristics
The correlations of the FrSBe scales with disease-specific aspects 
are outlined in Table  3. The strongest correlation was found 
between the family ratings and PPMS, especially in the disinhibi-
tion scale. Higher FrSBe test values before illness were indicative 
for pathological test results after illness.
correlation of Behavioral changes  
(FrsBe results) with cognitive and 
Behavioral Tests
The correlations of the FrSBe with all cognitive and behavioral 
tests are outlined in Table 4. The strongest and most consistent 
correlation was found between the FrSBe (self- and family rating) 
and the WEIMuS and BDI. Otherwise, only single significant cor-
relations were found as indicated in Table 4. In addition, the cor-
relation of the FrSBe with a frontal lobe test battery resembling the 
cognitive domain “Executive function” (= mean values of “Word 
fluency task,” “Design fluency task,” “Stroop’s color-word test III 
(mistakes),” “Stroop’s color-word test III (time),” “Planning test 
(number of moves),” “Planning test (quality total),” and “Kramer’s 
card sorting test”) showed a significant correlation to Executive 
dysfunctions (self-rating) of the FrSBe. All other correlations 
were not significant.
Multivariable linear Models of the FrsBe 
including BDi, WeiMus, and Frontal lobe 
Tests
We used multivariable linear models to investigate the con-
tribution of measures of depressive symptoms and/or fatigue 
concurrently with frontal lobe tests (Kramer test correct ones, 
Word fluency, Design fluency, and Planning test moves) to the 
current self-rating FrSBe scores. Data indicate that fatigue and 
depressive symptoms were in most cases significant predictors 
for FrSBe test results (only for WEIMuS did not predict disinhi-
bition), and frontal lobe tests were not.
DiscUssiOn
Up to one third of patients of our cohort showed behavioral 
changes in at least one domain (apathy, disinhibition, and execu-
tive dysfunction) or in the total score of the FrSBe. Apart from 
this, patients were rather mildly affected, especially with regard to 
cognitive functioning. Less than 10% of patients showed patho-
logical values in the performed cognitive tests with the exception 
of planning abilities and different aspects of attention that showed 
deficits in up to 23% of patients (Table 2).
There were no consistent correlations of behavioral changes 
with the EDSS, gender, disease duration, and MS type. Only PPMS 
consistently predicted the occurrence of behavioral symptoms in 
the family ratings, a finding that is, however, difficult to interpret 
due to the small PPMS sample (Table 3).
Cognitive impairments and especially frontal lobe dys-
function did not consistently predict behavioral changes as 
well. Only the mean value of the executive dysfunctions test 
battery, resembling a cognitive frontal lobe test battery, was 
TaBle 4 | Correlation between FrSBe and cognitive tests.
Tests FrsBe self-ratings FrsBe family ratings
apathy Disinhibition executive 
dysfunction
Total 
score
apathy Disinhibition executive 
dysfunction
Total 
score
Verbal memory
Verbal short-term memory −0.108 −0.04 −0.33† −0.17 0.12 −0.085 −0.14 −0.05
Auditory verbal learning and memory test (learning) −0.1 0.07 −0.05 −0.005 −0.02 0.05 0.05 0.04
Auditory verbal learning and memory test (long-term recall) 0.09 0.20 0.08 0.17 0.05 0.166 0.1 0.1
Logical Memory of the Wechsler Memory test −0.1055 −0.04 −0.24 −0.15 −0.25 −0.23 −0.25 −0.28*
Mean value of verbal memory tests −0.08 0.07 −0.18 −0.03 −0.02 −0.03 −0.08 −0.05
non-verbal memory
Visual short-term memory −0.086 0.035 −0.17 −0.16 −0.08 −0.1 −0.21 −0.14
Figural learning and memory test (learning) −0.023 0.285* 0.04 0.09 −0.18 0.04 −0.03 −0.05
Figural learning and memory test (long-term recall) 0.033 0.23 0.05 0.08 −0.20 0.02 −0.05 −0.085
Recall of Rey-Taylor complex figure test 0.14 0.05 0.08 0.12 −0.009 0.08 0.04 0.02
Mean value of non-verbal memory tests 0.03 0.16 −0.01 0.01 −0.13 −0.02 −0.07 −0.09
executive functions
Word fluency task −0.21 −0.06 −0.23 −0.22 −0.09 0.008 −0.14 −0.085
Design fluency task −0.06 −0.0007 −0.17 −0.13 −0.28* −0.21 −0.13 −0.23
Stroop’s color-word test III (mistakes) −0.05 0.01 −0.05 −0.03 0.11 0.21 0.15 0.1
Stroop’s color-word test III (time) −0.19 −0.19 −0.23 −0.19 −0.04 −0.13 −0.09 −0.12
Planning test (number of moves) −0.06 −0.135 −0.1 −0.12 −0.04 −0.21 −0.15 −0.14
Planning test (quality total) −0.02 −0.03 −0.03 −0.05 −0.003 −0.2 −0.14 −0.11
Kramer’s card sorting test 0.11 0.09 −0.14 −0.02 −0.01 −0.02 −0.02 −0.025
Mean value of Executive functions tests −0.17 −0.15 −0.27* −0.23 −0.09 −0.18 −0.19 −0.18
attention
Alertness without warning signal −0.25 0.13 −0.19 −0.175 −0.22 −0.19 −0.23 −0.24
Alertness with warning signal −0.09 0.07 −0.1 −0.09 −0.19 −0.13 −0.15 −0.18
Devided attention 0.18 0.21 0.19 0.25* 0.01 −0.12 0.03 −0.015
Test des deux barrages (total per minute) −0.03 0.2 −0.21 −0.001 −0.06 −0.035 −0.105 −0.07
Test des deux barrages (omission) −0.0026 0.34† 0.04 0.109 0.035 0.08 −0.002 0.05
Test des deux barrages (constancy) −0.19 −0.086 −0.24 −0.19 −0.14 −0.17 −0.236 −0.2
Modificated Trail Making test Form A −0.19 0.41† −0.11 0.006 −0.12 −0.136 −0.15 −0.13
Mean value of attention tests −0.21 0.22 −0.25 −0.12 −0.21 −0.17 −0.24 −0.23
Visuospatial abilities/visual perception tests
Rey-Taylor complex figure test (copy) 0.04 0.116 0.23 0.19 0.11 0.06 0.19 0.155
Spatial test −0.09 −0.23 −0.11 −0.115 −0.05 −0.04 0.03 0.015
Cortical Vision Screening test (maximum 38) −0.01 0.06 −0.18 −0.12 −0.03 0.1 −0.02 −0.004
Mean values of visuospatial abilities/visual perception tests −0.05 −0.21 −0.07 −0.09 0.03 0.04 0.04 0.07
neglect
Bells test (omissions; cut-off 6) 0.15 −0.15 0.06 0.056 0.03 −0.02 0.13 0.09
apraxia
Apraxia total −0.15 0.055 −0.136 −0.11 −0.13 −0.11 −0.1 −0.13
language
Token test (maximum 10) NA NA NA NA NA NA NA NA
Naming (maximum 10) −0.16 −0.13 −0.14 −0.17 −0.095 −0.09 −0.06 −0.08
Reading (maximum 10) NA NA NA NA NA NA NA NA
Writing (maximum 10) −0.04 −0.02 −0.13 −0.13 −0.13 −0.12 −0.17 −0.185
Mean values of Language tests −0.11 −0.08 −0.17 −0.18 −0.15 −0.16 −0.17 −0.19
Beck Depression inventory 0.58† 0.38† 0.57† 0.64† 0.42† 0.29* 0.42† 0.45†
WeiMus
WEIMuS physically, comparison with healthy controls 0.71† 0.246 0.59† 0.7† 0.45† 0.35† 0.48† 0.51†
WEIMuS cognitive, comparison with healthy controls 0.76† 0.266* 0.63† 0.765† 0.5† 0.335† 0.47† 0.51†
WEIMuS total, comparison with healthy controls 0.76† 0.276* 0.63† 0.76† 0.47† 0.34† 0.49† 0.51†
WEIMuS physically, comparison with MS patients 0.7† 0.23 0.6† 0.7† 0.45† 0.32* 0.49† 0.5†
WEIMuS cognitive, comparison with MS patients 0.76† 0.29* 0.65† 0.79† 0.48† 0.35† 0.48† 0.5†
total, comparison with MS patients 0.74† 0.27* 0.63† 0.75† 0.47† 0.34† 0.48† 0.5†
*p < 0.05
†p < 0.01.
WEIMuS, Wuerzburg Fatigue Inventory for Multiple Sclerosis; MS, multiple sclerosis; FrSBe, Frontal Systems Behavior Scale.
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significantly correlated with self-rating of executive dysfunctions 
of the FrSBe (Table 4).
Taken together, these results indicate that behavioral changes 
are present in a relevant proportion of otherwise mildly affected 
MS patients especially with regard to cognitive functioning. In 
these patients, behavioral changes occur largely independent 
of disease characteristics, physical disability, and cognitive 
impairments. Only depressive symptoms and fatigue were 
strongly associated with behavioral changes, a finding that 
was well established from previous studies (9, 28). Therefore, 
the existence of behavioral changes in MS patients cannot be 
necessarily anticipated from the performed clinical outcome 
measurements. For this reason, behavioral changes should be 
specifically tested, which is of importance because behavioral 
changes are relevant impairments that negatively influence 
the daily life of patients and working ability (6). In addition, 
alternative diagnostic tools to predict or diagnose behavioral 
changes would be of great interest. Magnetic resonance imag-
ing (MRI) studies, especially cortical thickness and deep gray 
matter volumetry, have been shown to correlate with cognitive 
impairment and behavioral changes such as depression (29, 30). 
Therefore, MRI studies were performed in all patients in this 
study including the analysis of cortical thickness and cortical 
lesions that will be assessed in 33 different anatomical brain 
areas using a T1-modified driven equilibrium Fourier transform 
sequence and double inversion recovery sequence, respectively. 
This currently ongoing analysis aims to examine potential cor-
relations between cortical pathologies and behavioral changes 
(beside depression and fatigue).
In contrast to our study, Chiaravalloti and DeLuca found sig-
nificant correlations between cognitive impairments and behav-
ioral changes also analyzed by the FrSBe (9). This is probably due 
to a presumably more cognitive impaired patient cohort in the 
Chiaravalloti study compared to our cohort. However, an exact 
comparison of both cohorts is not possible due to the different 
assessments of disability and cognitive functioning in both stud-
ies. Overall, our study therefore adds important information on 
behavioral changes in physically and cognitively mildly affected 
MS patients, which broadens the knowledge about behavioral 
changes in MS patients.
Behavioral changes were reported more often after illness 
compared to before illness (Figure  1) and self- and family 
ratings of the current behavioral status were equal in most 
scores (Figure  2), which is in line with the study performed 
by Chiaravalloti and DeLuca (9). These findings are of interest 
because self- and family ratings of behavioral changes as well as 
cognitive impairments in MS patients showed large discrepancies 
in previous studies that did not use the FrSBe for the evaluation of 
behavioral changes (13, 14). In addition, self- and family ratings 
of behavioral changes usually differ substantially in other brain 
diseases such as traumatic brain injuries or brain tumors (15–17).
These results indicate suggest that the FrSBe is suitable for 
the reliable evaluation of behavioral changes asking both, the 
MS patients or family members and can be used in the daily 
routine.
study limitations
The study was performed in a mildly affected MS patient cohort 
especially with regard to cognitive functioning, and therefore, 
conclusions for moderately to severely affected patients cannot 
be made. The tests used in this study are validated and existing 
normative values were compared to the results of our study popu-
lation. However, we did not include an own control group and did 
therefore not account for differences, which might be population 
specific to our group. Validated subjectively reported outcome 
measurements, answered by patients and family members, were 
used in the study. Furthermore, the number of CIS and PPMS 
patients was low rendering any conclusions impossible.
cOnclUsiOn
Behavioral changes are common even in otherwise mildly affected 
MS patients with up to one third of patients being affected. They 
occur largely independently of disease characteristics, physical 
disability, and cognitive functioning but correlate with both 
fatigue and depressive symptoms. Therefore, behavioral changes 
can not necessarily be anticipated in MS patients and should be 
specifically evaluated to obtain a more comprehensive picture 
of patients’ symptoms. By using the FrSBe, patients and family 
members can be asked with regard to behavioral changes.
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